Issuer-Sponsored by Tiziana Life Sciences*

TODAY’S TOP ALERT!

Nasdaq: TLSA

📈 Join us for LIVE TRADING action all day long in the 📈

Good morning, team!

Stock futures are more green than my Christmas tree 🎄 this AM after Salesforce posted strong earnings after the bell yesterday.

The $300+ billion company is up ~13% in the pre-market as of this writing.

As I wrote on Monday, “There’s no stopping this Santa Rally 🎅🏻, folks, so the grinches can go pout in their cave while the rest of us profit.”

Meanwhile, my “tactical trade” idea from yesterday has ripped as high as 11% in the pre-market after a solid 8.5% gain yesterday.

That was one of my favorite small companies so I’m glad to see it doing so well.

This morning, I’m revisiting another one of my favorites…

It’s a small biotech company that’s up an impressive 60% YTD. The last time I brought it to your attention, it went on to have an incredible day:

At one point, it ranked in the top-20 movers in the entire market that day.

Now that I’ve given the company away, go ahead and pull up the chart for Tiziana Life Sciences Ltd (TLSA).

If you look especially at the chart for the last six months, you’ll see the stock has been funneling into an ever-more-narrow wedge:

As I wrote to you last night, “I think the right news could lead to a breakout,” and I came across chatter on the forums that such news might be dropping “imminently.”

Well, just a few minutes ago, the company dropped big news of an expansion of their Phase 2 trial (more on that below) to include trial sites at prestigious institutions such as:

Yale University
Johns Hopkins University
Cornell University
University at Buffalo (SUNY)
University of Massachusetts (UMass)
Thomas Jefferson University

TLSA CEO Ivor Elrifi said the company was “honored to collaborate with these prestigious institutions as we further expand our clinical trial.”

According to TipRanks, the stock is up 10% in the pre-market, so it looks like this was precisely what the company needed for a breakout.

Keep a close eye on TLSA as all the action plays out.

Here are some things that jumped out at me that help explain why the company has done so well overall this year…

Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biopharmaceutical company developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases with high unmet needs.

Its lead candidate, Foralumab, is a monoclonal antibody therapy that reduces inflammation by targeting a protein on T cells called CD3.

One of TLSA’s key innovations is to administer Foramulab intranasally, producing minimal toxicity while creating local T cells that more easily cross the blood-brain barrier.

The upshot is that Foramulab may help suppress the activation of the brain’s most prominent immune cells — called “microglial cells” — which are overactive in diseases such as multiple sclerosis and Alzheimer’s.

While there are other therapies that target CD3, Foralumab is the only CD3-targeting monoclonal antibody that is “fully human.” In theory, this should minimize adverse immune responses.

A similar anti-CD3 molecule that is only “humanized,” Teplizumab, was recently acquired by French pharma giant Sanofi for $2.9 billion.

Already, Foramulab has shown incredible promise at reducing microglial activation.

In April, TLSA presented data at the annual meeting of the American Academy of Neurology showing that nasal Foramulab “exhibited a reduction in microglial activation and disease stabilization in non-active secondary progressive multiple sclerosis [na-SPMS] patients … as observed through positron emission tomography (PET) imaging.”

Dr. Tarun Singhal, an associate professor at Harvard Medical School, authored the study, noting that it “provides initial evidence that this fully human anti-CD3 has the potential to benefit this type of MS, which is the most difficult form to treat.”

Those findings were reinforced when the company announced in June that “80% of the na-SPMS patients who received intranasal foralumab treatment for at least 6-months have a qualitative reduction of microglial activity” as confirmed in PET images.

Furthermore, 70% of patients experienced a meaningful reduction in fatigue scores, and stability of disease was noted within six months in all ten na-SPMS patients.

In May, TLSA applied for Orphan Drug Designation for intranasal foralumab for the treatment of na-SPMS, and in July, the FDA granted it a Fast Track Designation for treatment of the disease.

Fast Track will provide TLSA with an expedited review process and increased interaction with the FDA.

Based on population prevalence data, TLSA estimates there are 94,000 na-SPMS patients in the US and 155,000 in the EU.

But that form of multiple sclerosis isn’t the only potential indication for Foramulab…

TLSA has also received Investigational New Drug clearance from the FDA for Foramulab as a treatment for Alzheimer’s, and in September, the company announced a prestigious $4 million grant from the National Institutes of Health to Dr. Howard Weiner as principal investigator at Brigham and Women’s Hospital to study nasal anti-CD3 for the treatment of Alzheimer’s disease.

The company said the grant “represents a major milestone in Tiziana’s development pipeline” that will advance preclinical and, ultimately, clinical studies of intranasal anti-CD3 as a treatment for Alzheimer’s.

TLSA is also investigating the therapy for Long Covid, which is estimated to cost the US healthcare system almost $2.6 trillion.

In late October, the company dropped huge news:

The study — conducted by Dr. Howard Weiner and Selma Boulenouar PhD, and a research team at Brigham and Women’s Hospital in Boston — found that “Nasal anti-CD3 in combination with semaglutide [Ozempic] demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity.”

It also found that “The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders.”

As I’m sure you’re aware, Ozempic is perhaps the hottest drug on the market right now, and this study suggests TLSA’s drug candidate may be a powerful complement to it.

And two weeks ago, the company revealed it was awarded a prestigious grant from the ALS Association to fund a 20-patient clinical trial of intranasal foralumab as a treatment for Amyotrophic Lateral Sclerosis (ALS), better known as Lou Gehrig’s disease.

TLSA’s pipeline

Dr. Matthew W. Davis, chief medical officer of TLSA, notes that, “We have now seen the potential of intranasal foralumab to dampen microglial activation in three major neuroinflammatory-related diseases, which creates significant optionality for exploring its benefits in some of the most important and burdensome medical conditions of our time.”

Those are some notes on TLSA to jumpstart your own research. You should be sure to check out this investor presentation from August and the company’s very informative website.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose.

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: TLSA’s stock has been funneling into an ever-more-narrow wedge over the several months, and the company just dropped big news this morning that has sent it up double-digits in the pre-market.

This could be a banner day for the stock if it breaks out of the wedge to the upside. Put TLSA at the top of your watchlist right away!

To Your Success,

Jeff Bishop

*Issuer Paid Content. Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we were paid thirty five thousand dollars directly from Tiziana Life Sciences Ltd for a one day marketing program on December 4, 2024. Previously, we were paid thirty thousand dollars directly from Tiziana Life Sciences Ltd for a one-day marketing program on October 30, 2024. We also received seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on June 6, 2024. Before that, we were paid seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on April 22, 2024. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Tiziana Life Sciences Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.